Smith+Nephew receives Innovative Technology designation from Vizient for LEAF™ Patient Monitoring System
Designation recognizes Vizient-contracted products that bring improvements to healthcare industry
LONDON, Jan. 30, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its LEAF Patient Monitoring System has received an Innovative Technology designation from Vizient, Inc., the largest healthcare performance improvement company in the United States. Smith+Nephew exhibited the LEAF Patient Monitoring System at the Vizient Innovative Technology Exchange on October 17th in Dallas, Texas.
Every year, healthcare experts serving on Vizient member-led councils review select products and technologies for their potential to enhance clinical care, patient safety, healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal to healthcare providers the impact of these innovations on patient care and business models of healthcare organizations.
The LEAF Patient Monitoring System is the first wearable, wireless solution which meets the recommendations in the National Pressure Injury Advisory Panel (NPIAP) guidelines.1 The LEAF System is proven to help improve adherence to individualized turn protocols up to 98%2,3* and has been shown to help reduce the chance of developing Hospital-acquired pressure injuries (HAPIs) by 73%.3†
The use of the LEAF System helped improve nursing efficiencies,4,5 and generated up to $1.8 million estimated annual cost savings in one facility's critical care units.4,6
"We are very proud to receive the Innovative Technology designation from Vizient. Pressure injuries are the only hospital acquired complication on the rise in the US, costing roughly $11B in preventable treatments, with dire impact to those patients affected," said Paolo Di Vincenzo, Senior Vice President US Commercial, Advanced Wound Management for Smith+Nephew. "We will not settle until we've solved this challenge and are excited for the role our LEAF Patient Monitoring System will play - fast becoming a standard of patient care in the U.S. and reducing facility costs."
The LEAF System indications, contraindications, warnings, precautions and other important information can be found in the product's Instructions for Use.
† In acutely ill patients in ICU compared to traditional turning methods from 2.7% to 0.7%; p = 0.012
1. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. Emily Haesler (Ed.) EPUAP/NPIAP/PPPIA: 2019. 2. Schutt SC, Tarver C, Pezzani M. Pilot study: Assessing the effect of continual position monitoring technology on compliance with patient turning protocols. Nurs Open. 2017;5(1):21-28.
3. Pickham D, Berte N, Pihulic M, Valdez A, Mayer B, Desai M. Effect of a wearable patient sensor on care delivery for preventing pressure injuries in acutely ill adults: A pragmatic randomized clinical trial (LS-HAPI study). Int J Nurs Stud. 2018;80:12-19.
4. Smith+Nephew 2020.Leveraging novel technology to decrease hospital-acquired pressure injuries. Internal Report. EO.AWM.PCS006.001.v1.
5. Rogers M. Reducing Hospital-Acquired Pressure Injuries (HAPI) in Long-term Acute Care with Turn Cueing Technology. Poster presented at: American Organization for Nursing Leadership; March 18- March 21, 2020; Nashville, Tennessee, USA.
6. Gasparini R, Derisma Q, Hannon R. "Turning" to Technology: Reducing Hospital Acquired Pressure Injuries in Critical Care with Visual Turn Cueing. Poster presented at: National Pressure Injury Advisory Panel Annual Conference; March 10- March 12, 2021; Virtual Conference.
Vizient represents a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and represents approximately $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
View original content to download multimedia:https://www.prnewswire.com/news-releases/smithnephew-receives-innovative-technology-designation-from-vizient-for-leaf-patient-monitoring-system-301732440.html
SOURCE Smith & Nephew plc
Upcoming Life Sciences Events
- March 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023
- Brussels: Cell and Gene Therapy Summit
Latest company news
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Asia Pacific Mammography Devices Market Analysis Report 2022: Focus on China, India, Japan, South Korea, Australia, New Zealand, Malaysia, Vietnam, Indonesia, & Singapore